Speech profile in different clinical PSP phenotypes: an acoustic-perceptual study.

Acoustic speech analysis Atypical parkinsonism PSP PSP classification Phenotype Progressive supranuclear palsy

Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
25 Oct 2024
Historique:
received: 01 09 2024
accepted: 17 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: aheadofprint

Résumé

Progressive supranuclear palsy (PSP) is a neurodegenerative disease with pathological hallmarks and different clinical presentations. Recently, the Movement Disorder Society (MDS) promoted a new classification; specific combinations of the core clinical features identify different phenotypes, including PSP with Richardson's syndrome (PSP-RS) and PSP with predominant parkinsonism (PSP-P). Since speech disorders are very common in PSP, they were included in the MDS-PSP criteria as a supportive clinical feature in the form of hypokinetic, spastic dysarthria. However, little is known about how dysarthria presents across the different PSP variants. The aim of the present study is to evaluate the presence of differences in speech profile in a cohort of PSP-RS and PSP-P patients diagnosed according to the MDS-PSP criteria. Each patient underwent a neurological evaluation and perceptual and acoustic analysis of speech. Disease severity was rated using the Natural History and Neuroprotection in Parkinson plus syndromes-Parkinson plus scale (NNIPPS-PPS), including global score and sub-scores. Twenty-five patients (mean disease duration [standard deviation] = 3.32 [1.79]) were classified as PSP-RS, while sixteen as PSP-P (mean disease duration [standard deviation] = 3.47 [2.00]). These subgroups had homogeneous demographical and clinical characteristics, including disease severity quantified by the NNIPPS-PPS total score. Only the NNIPPS-PPS oculomotor function sub-score significantly differed, being more impaired in PSP-RS patients. No significant differences were found in all speech variables between the two groups. Speech evaluation is not a distinguishing feature of PSP subtypes in mid-stage disease.

Identifiants

pubmed: 39453558
doi: 10.1007/s10072-024-07833-w
pii: 10.1007/s10072-024-07833-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : Ministero della Salute

Informations de copyright

© 2024. Fondazione Società Italiana di Neurologia.

Références

Coughlin DG, Litvan I (2020) Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord 73:105–116
doi: 10.1016/j.parkreldis.2020.04.014 pubmed: 32487421 pmcid: 7462164
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864
doi: 10.1002/mds.26987 pubmed: 28467028 pmcid: 5516529
Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766
doi: 10.1002/mds.26054 pubmed: 25370486
Skodda S, Visser W, Schlegel U (2011) Acoustical analysis of speech in progressive supranuclear palsy. J Voice 25:725–731
doi: 10.1016/j.jvoice.2010.01.002 pubmed: 20457507
Rusz J, Bonnet C, Klempíř J et al (2015) Speech disorders reflect differing pathophysiology in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. J Neurol 262:992–1001
doi: 10.1007/s00415-015-7671-1 pubmed: 25683763
Daoudi K, Das B, Tykalova T, Klempir J, Rusz J (2022) Speech acoustic indices for differential diagnosis between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. NPJ Parkinsons Dis 8:142
doi: 10.1038/s41531-022-00389-6 pubmed: 36302780 pmcid: 9613976
Payan CAM, Viallet F, Landwehrmeyer BG et al (2011) Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS–Parkinson plus scale. PLoS ONE 6:e22293
doi: 10.1371/journal.pone.0022293 pubmed: 21829612 pmcid: 3150329
Boersma P, Weenink D, Praat (2013) Doing phonetics by computer [Computer Program]. Version 5.3.51. [online]. Accessed at: Available online at: http://www.praat.org/ (accessed June 2, 2013)
Cavallieri F, Gessani A, Merlo A et al (2023) Interplay between speech and gait variables in Parkinson’s disease patients treated with subthalamic nucleus deep brain stimulation: a long-term instrumental assessment. Eur J Neurol 30:1963–1972
doi: 10.1111/ene.15803 pubmed: 36971736
Rusz J, Tykalova T, Ramig LO, Tripoliti E (2021) Guidelines for speech recording and acoustic analyses in dysarthrias of movement disorders. Mov Disord 36:803–814
doi: 10.1002/mds.28465 pubmed: 33373483
Phokaewvarangkul O, Bhidayasiri R (2019) How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Transl Neurodegener 8:20
doi: 10.1186/s40035-019-0160-1 pubmed: 31333840 pmcid: 6617936
Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, Höglinger GU (2021) Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat Rev Neurol 17:601–620
doi: 10.1038/s41582-021-00541-5 pubmed: 34426686
Kluin K, Gilman S, Foster N et al (2001) Neuropathological correlates of dysarthria in progressive supranuclear palsy. Arch Neurol 58:265–269
doi: 10.1001/archneur.58.2.265 pubmed: 11176965
Kluin KJ, Foster NL, Berent S, Gilman S (1993) Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology 43:563–566
doi: 10.1212/WNL.43.3_Part_1.563 pubmed: 8451002
Clark HM, Utianski RL, Ali F et al. (2021) Motor speech disorders and communication limitations in progressive supranuclear palsy. Am J Speech Lang Pathol 30(3S):1361–1372
Goetz CG, Leurgans S, Lang AE, Litvan I (2003) Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 60:917–922
doi: 10.1212/01.WNL.0000052686.97625.27 pubmed: 12654953
Maslan J, Leng X, Rees C, Blalock D, Butler SG (2011) Maximum phonation time in healthy older adults. J Voice 25:709–713
doi: 10.1016/j.jvoice.2010.10.002 pubmed: 21439778 pmcid: 3128209
Kent RD, Kent JF, Rosenbek JC (1987) Maximum performance tests of speech production. J Speech Hear Disord 52:367–387
doi: 10.1044/jshd.5204.367 pubmed: 3312817
Cavallieri F, Di Rauso G, Gessani A et al (2023) A study on the correlations between acoustic speech variables and bradykinesia in advanced Parkinson’s disease. Front Neurol 14:1213772
doi: 10.3389/fneur.2023.1213772 pubmed: 37533469 pmcid: 10393249
de Angelis EC, Mourão LF, Ferraz HB, Behlau MS, Pontes PA, Andrade LA (1997) Effect of voice rehabilitation on oral communication of Parkinson’s disease patients. Acta Neurol Scand 96:199–205
doi: 10.1111/j.1600-0404.1997.tb00269.x pubmed: 9325469
Gamboa J, Jiménez-Jiménez FJ, Nieto A et al (1997) Acoustic voice analysis in patients with Parkinson’s disease treated with dopaminergic drugs. J Voice 11:314–320
doi: 10.1016/S0892-1997(97)80010-0 pubmed: 9297676
Yücetürk A, Yılmaz H, Eğrilmez M, Karaca S (2002) Voice analysis and videolaryngostroboscopy in patients with Parkinson’s disease. Eur Arch Otorhinolaryngol 259:290–293
doi: 10.1007/s00405-002-0462-1 pubmed: 12115074
De Letter M, Santens P, De Bodt M, Van Maele G, Van Borsel J, Boon P (2007) The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson’s disease. Clin Neurol Neurosurg 109:495–500
doi: 10.1016/j.clineuro.2007.04.003 pubmed: 17509751

Auteurs

Giulia Di Rauso (G)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Francesco Cavallieri (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Annalisa Gessani (A)

Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Davide Fontanesi (D)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Serena Coniglio (S)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Valentina Fioravanti (V)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Sara Contardi (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italy.

Elisa Menozzi (E)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Francesca Antonelli (F)

Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Vittorio Rispoli (V)

Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. vit.rispoli@gmail.com.

Franco Valzania (F)

Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Carla Budriesi (C)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Neurology, Neuroscience Head Neck Department, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.

Classifications MeSH